Sulfur‐Fumigation Engineered Ceria Nanoparticles With Augmented Oxygen Vacancies for Enhanced Therapy of Drug‐Induced Liver Injury

Why It Matters

The breakthrough offers a more potent, organ‑specific antioxidant platform, addressing the unmet need for effective DILI therapies and advancing nanomaterial design for clinical use.

Key Takeaways

• Sulfur fumigation reshapes ceria crystal facets to (200) and (220).
• Modified nanoparticles exhibit increased oxygen vacancies and ROS scavenging.
• Hydrodynamic size (~136 nm) enables efficient liver accumulation.
• In DILI mouse model, outperformed N‑acetylcysteine.
• Strategy offers scalable post‑synthesis nanomaterial enhancement.

Pulse Analysis

Drug‑induced liver injury (DILI) remains a leading cause of acute hepatic failure, driven largely by excessive reactive oxygen species (ROS) that trigger inflammation and cell death. Conventional antioxidants such as N‑acetylcysteine provide limited protection and require high dosing. Nanoceria, a rare‑earth oxide, has attracted attention because its Ce³⁺/Ce⁴⁺ redox couple can continuously neutralize ROS, offering a self‑renewing scavenging platform. Yet, translating ceria nanoparticles into effective DILI therapeutics has been hampered by modest activity and suboptimal organ retention. Therefore, optimizing nanoceria surface chemistry emerges as a critical frontier for next‑generation hepatoprotective therapies.

A recent study introduces sulfur fumigation as a post‑synthesis surface‑engineering tool that selectively exposes low‑index (200) and (220) crystal planes on ceria nanospheres. This facet modulation contracts the lattice and induces crystalline fusion, dramatically increasing oxygen‑vacancy concentration despite a reduced surface area. The resulting particles possess a hydrodynamic diameter of roughly 136 nm, ideal for passive liver targeting via the sinusoidal endothelium. Enhanced vacancy density translates into superior ROS‑scavenging kinetics, allowing the nanoceria to quench oxidative bursts more efficiently than untreated counterparts.

In murine DILI models, sulfur‑fumed ceria nanoparticles accumulated rapidly in hepatic tissue and attenuated markers of oxidative stress, inflammatory cytokines, and apoptotic signaling more effectively than the clinical benchmark N‑acetylcysteine. The therapeutic advantage stems from the combination of prolonged hepatic residence and amplified redox activity, reducing the required dose and minimizing off‑target exposure. This approach showcases how post‑synthetic facet engineering can unlock latent functionality in existing nanomaterials, paving the way for scalable, high‑performance antioxidants in liver disease and beyond. Future work will focus on long‑term safety, manufacturing reproducibility, and regulatory pathways for clinical translation.